| Lymphoma, Follicular
Rituxan Hycela vs Tazverik
Side-by-side clinical, coverage, and cost comparison for lymphoma, follicular.Deep comparison between: Rituxan Hycela vs Tazverik with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsTazverik has a higher rate of injection site reactions vs Rituxan Hycela based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Tazverik but not Rituxan Hycela, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Rituxan Hycela
Tazverik
At A Glance
SC injection
Every 3-4 weeks
CD20-directed antibody
Oral
Twice daily
EZH2 methyltransferase inhibitor
Indications
- Lymphoma, Follicular
- Diffuse Large B-Cell Lymphoma
- Chronic Lymphocytic Leukemia
- Sarcoma, Epithelioid
- Lymphoma, Follicular
Dosing
Lymphoma, Follicular 1,400 mg/23,400 Units SC; for relapsed/refractory FL, once weekly for 3 or 7 weeks following an initial IV rituximab dose (4 or 8 weeks total); for previously untreated FL, on Day 1 of Cycles 2-8 of chemotherapy every 21 days, then maintenance every 8 weeks for 12 doses; for non-progressing FL after CVP, once weekly for 3 weeks every 6 months to a maximum of 16 doses.
Diffuse Large B-Cell Lymphoma 1,400 mg/23,400 Units SC on Day 1 of Cycles 2-8 of CHOP chemotherapy every 21 days for up to 7 cycles following an initial IV rituximab dose at Day 1, Cycle 1 (up to 6-8 cycles total).
Chronic Lymphocytic Leukemia 1,600 mg/26,800 Units SC on Day 1 of Cycles 2-6 in combination with fludarabine and cyclophosphamide every 28 days for 5 cycles following an initial IV rituximab dose at Day 1, Cycle 1 (6 cycles total).
Sarcoma, Epithelioid 800 mg orally twice daily with or without food until disease progression or unacceptable toxicity.
Lymphoma, Follicular 800 mg orally twice daily with or without food until disease progression or unacceptable toxicity; select patients based on EZH2 mutation of codons Y646, A682, or A692 for EZH2-mutant R/R FL.
Contraindications
—
—
Adverse Reactions
Most common (>=20%) Infections, neutropenia, nausea, constipation, cough, fatigue (FL); infections, neutropenia, alopecia, nausea, anemia (DLBCL); infections, neutropenia, nausea, thrombocytopenia, pyrexia, vomiting, injection site erythema (CLL).
Serious Mucocutaneous reactions, hepatitis B reactivation, progressive multifocal leukoencephalopathy, hypersensitivity and administration reactions, tumor lysis syndrome, infections, cardiac arrhythmias, renal toxicity, bowel obstruction and perforation.
Postmarketing Prolonged pancytopenia, fatal cardiac failure, uveitis, viral infections including PML, Kaposi's sarcoma progression, severe mucocutaneous reactions, pyoderma gangrenosum, bowel obstruction and perforation, fatal bronchiolitis obliterans, fatal interstitial lung disease.
Most common (>=20%) - Sarcoma, Epithelioid pain, fatigue, nausea, decreased appetite, vomiting, constipation
Most common (>=20%) - Lymphoma, Follicular fatigue, upper respiratory tract infection, musculoskeletal pain, nausea, abdominal pain
Serious - Sarcoma, Epithelioid hemorrhage, pleural effusion, skin infection, dyspnea, pain, respiratory distress
Serious - Lymphoma, Follicular general physical health deterioration, abdominal pain, pneumonia, sepsis, anemia
Pharmacology
Anti-CD20 chimeric murine/human IgG1 monoclonal antibody that binds the CD20 antigen on pre-B and mature B-lymphocytes, mediating B-cell lysis via complement dependent cytotoxicity (CDC) and antibody dependent cell mediated cytotoxicity (ADCC); combined with hyaluronidase human, which transiently depolymerizes subcutaneous hyaluronan to enhance rituximab absorption into systemic circulation.
Tazemetostat is a selective inhibitor of EZH2 methyltransferase and certain gain-of-function mutations (Y646X, A682G, A692V), blocking trimethylation of histone H3 lysine 27 and relieving transcriptional repression that drives tumor growth in epithelioid sarcoma (via SWI/SNF complex dysfunction) and B-cell lymphoma with or without EZH2 mutation.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Rituxan Hycela
- Covered on 5 commercial plans
- PA (5/12) · Step Therapy (0/12) · Qty limit (0/12)
Tazverik
- Covered on 5 commercial plans
- PA (11/12) · Step Therapy (0/12) · Qty limit (3/12)
UnitedHealthcare
Rituxan Hycela
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Tazverik
- Covered on 4 commercial plans
- PA (6/8) · Step Therapy (0/8) · Qty limit (2/8)
Humana
Rituxan Hycela
- Covered on 0 commercial plans
- PA (2/3) · Step Therapy (2/3) · Qty limit (2/3)
Tazverik
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Rituxan Hycela.
Cost estimate not availableCancerCare: Non-Hodgkin Lymphoma
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
Rituxan HycelaView full Rituxan Hycela profile
TazverikView full Tazverik profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.